By PPN News Staff
The FDA granted a new indication for dupilumab (Dupixent, Regeneron/Sanofi) for children aged 6 to 11 years with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Dupilumab is the only biological medicine approved for this patient population.